All In Biotech

Drug Trial Radar · NCT06922045

Phase III Clinical Trial of STSP-0601 for Injection in Hemophilia Patients

A Phase III Clinical Study on the Efficacy and Safety of STSP-0601 for Injection in Patients With Hemophilia Associated With Inhibitors, With a Multicenter, Open Evaluation Approach

Last checked: Nov 19, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

40

Actual

Start

Mar 26, 2025

Primary completion

Sep 2026

Study completion Mar 2027

Sponsor

Sponsor type
Industry
First posted
Apr 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the efficacy of multiple-dose of STSP-0601 for the treatment of bleeding episodes in hemophilia A or B patients with inhibitor

Conditions

  • Hemophilia

Interventions

  • STSP-0601 for InjectionDrug

    Evaluation of the Efficacy of Single-Dose and Continuous Administration of STSP-0601 Injection for the Treatment of Bleeding in Patients with Hemophilia A or B with Inhibitors

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 12 hours effective hemostasis rateTime frame: 12 hours after the first administration

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Anhui Provincial Hospital

    Hefei, Anhui, China

  • Lanzhou University First Hospital

    Lanzhou, Gansu, China

  • Nanfang Hospital, Southern Medical University

    Guangzhou, Guangdong, China

  • Shenzhen Second People's Hospital

    Shenzhen, Guangdong, China

  • The First affiliated hospital of Guangxi Medical University

    Nanning, Guangxi, China

  • North China University of Science and Technology Affiliated Hospital

    Tangshan, Hebei, China

  • Harbin First Hospital Hematology Tumor Research Center

    Harbin, Heilongjiang, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Huazhong University of Science and Technology Union Hospital

    Wuhan, Hubei, China

  • Jiangsu Provincial Hospital

    Nanjing, Jiangsu, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • Jinan Central Clinical College of Shandong First Medical University

    Jinan, Shandong, China

  • Second hospital of Shanxi Medical University

    Taiyuan, Shanxi, China

  • Xi'an Central Hospital

    Xi’an, Shanxi, China

  • Sichuan Academy of Medical Sciences&Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China

  • Hospital of Hematology, Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, China

  • The Second Affiliated Hospital of Kunming Medical University

    Kunming, Yunnan, China

  • Wenzhou People's Hospital

    Wenzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.